RELATLIMAB
RELATLIMAB is listed in the FDA National Drug Code directory with 1 NDC code. Available dosage form: injection.
Drug Details
- Generic Name
- RELATLIMAB
- Brand Names
- N/A
- Application Number
- Sponsor
- Bristol-Myers Squibb Company
- NDC Codes
- 1
- Dosage Forms
- INJECTION
- Routes
- N/A
- Active Ingredients
- RELATLIMAB
Indications and Usage
1 INDICATIONS AND USAGE OPDUALAG™ is indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. OPDUALAG is a combination of nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody, indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. (1)